Sildenafil treats pulmonary arterial hypertension (PAH) by selectively inhibiting phosphodiesterase type 5 (PDE5).
Increased cGMP Levels
This inhibition leads to increased levels of cyclic guanosine monophosphate (cGMP). Higher cGMP levels relax pulmonary vascular smooth muscle.
Vascular Effects
- Improved pulmonary artery vasodilation. Reduced pulmonary vascular resistance. Increased pulmonary blood flow.
Other Beneficial Effects
Beyond vasodilation, Sildenafil also shows promise in modulating other PAH-related processes. Research suggests potential effects on:
Reducing pulmonary artery remodeling. Improving right ventricular function. Decreasing inflammation.
Dosage Considerations
Optimal Sildenafil dosage for PAH varies significantly depending on individual patient factors. Always follow your doctor’s specific recommendations.
Important Note:
While Sildenafil offers significant benefits, it’s crucial to be aware of potential side effects and carefully monitor your health during treatment. Consult your physician for any concerns.
